Last reviewed · How we verify

NCT03943498

Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy

Completed EARLY_PHASE1 Last updated 11 September 2023
What this trial tests

EARLY_PHASE1 trial testing Fingolimod in Chemotherapy-Induced Peripheral Neuropathy in 2 participants. Completed in 10 December 2020.

Timeline
24 May 2019
Primary endpoint
10 December 2020
10 December 2020

Quick facts

Lead sponsorMayo Clinic
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment2
Start date24 May 2019
Primary completion10 December 2020
Estimated completion10 December 2020
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Chemotherapy-Induced Peripheral Neuropathy or Numbness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This early phase I trial studies how well fingolimod works in treating patients with chemotherapy-induced nerve pain (neuropathy). Fingolimod acts by suppressing immune reactions in the brain. This study is being done to see if fingolimod can reduce neuropathy caused by chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
    Yamamoto S, Egashira N. · · 2021 · cited 86× · PMID 33477371 · DOI 10.3390/ijms22020888
  2. The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.
    Lucaciu A, Brunkhorst R, Pfeilschifter JM, Pfeilschifter W, et al · · 2020 · cited 53× · PMID 32580348 · DOI 10.3390/cells9061515
  3. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development.
    Yang Y, Zhao B, Gao X, Sun J, et al · · 2021 · cited 47× · PMID 34686205 · DOI 10.1186/s13046-021-02141-z
  4. Targeting the Sphingosine-1-Phosphate Axis for Developing Non-narcotic Pain Therapeutics.
    Squillace S, Spiegel S, Salvemini D. · · 2020 · cited 38× · PMID 33010954 · DOI 10.1016/j.tips.2020.09.006
  5. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy.
    Li Y, Lustberg MB, Hu S. · · 2021 · cited 36× · PMID 33673136 · DOI 10.3390/cancers13040766
  6. Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back.
    Geisler S. · · 2021 · cited 30× · PMID 33129841 · DOI 10.1016/j.expneurol.2020.113519
  7. Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
    Chua KC, Xiong C, Ho C, Mushiroda T, et al · · 2020 · cited 30× · PMID 32562552 · DOI 10.1002/cpt.1958
  8. Drug Repurposing to Target Neuroinflammation and Sensory Neuron-Dependent Pain.
    Sisignano M, Gribbon P, Geisslinger G. · · 2022 · cited 23× · PMID 35254645 · DOI 10.1007/s40265-022-01689-0

Verify or expand the search:

Other trials of Fingolimod

Trials testing the same drug.

Other recruiting trials for Chemotherapy-Induced Peripheral Neuropathy

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03943498.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing